A5032681199- Cell death mechanisms and regulation
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Cytokine Signaling Pathways and Interactions
- Hepatitis B Virus Studies
- Parasites and Host Interactions
- Cancer-related Molecular Pathways
- Mast cells and histamine
- Biochemical and Molecular Research
- Phagocytosis and Immune Regulation
- Cutaneous lymphoproliferative disorders research
- Escherichia coli research studies
- Cancer Mechanisms and Therapy
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Helminth infection and control
- Reproductive System and Pregnancy
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- Hepatocellular Carcinoma Treatment and Prognosis
Instytut Hematologii i Transfuzjologi
2018-2022
University of Warsaw
2016-2018
Abstract Spleen tyrosine kinase (SYK) is an important oncogene and signaling mediator activated by cell surface receptors crucial for acute myeloid leukemia (AML) maintenance progression. Genetic or pharmacologic inhibition of SYK in AML cells leads to increased differentiation, reduced proliferation, cellular apoptosis. Herein, we addressed the consequences stem-cell (LSC) function assessed SYK-associated pathways biology. Using gain-of-function MEK mutant constitutively active STAT5A,...
Abstract Lymph node microenvironment provides chronic lymphocytic leukaemia ( CLL ) cells with signals promoting their survival and granting resistance to chemotherapeutics. overexpress PIM kinases, which regulate apoptosis, cell cycle migration. We demonstrate that BCR crosslinking, CD 40 stimulation, coculture stromal increases s expression in cells, indicating microenvironment‐dependent regulation. 1 2 at diagnosis was higher patients advanced disease (Binet C vs. Binet A/B) those, who...
Abstract Mutations in isocitrate dehydrogenase 1 and 2 ( IDH1/2 ) genes occur about 20% patients with acute myeloid leukemia (AML), leading to DNA hypermethylation epigenetic deregulation. We assessed the prognostic significance of mutations + 398 AML normal karyotype (NK-AML), treated daunorubicine cytarabine (DA), DA cladribine (DAC), or fludarabine. IDH2 mutation was an independent favorable factor for 4-year overall survival (OS) total NK-AML population (p = 0.03, censoring at...
TRAIL (TNF-related apoptosis inducing ligand) exhibits selective proapoptotic activity in multiple tumor types, while sparing normal cells. This selectivity makes an attractive therapeutic candidate. However, despite encouraging preclinical models, clinical trials with mimetics/death receptor agonists demonstrated insufficient activity, largely due to emerging resistance these agents. Herein, we investigated the cytotoxic of a novel, TRAIL-based chimeric protein AD-O51.4 combining and...
Background: Burkitt lymphoma (BL) is a highly proliferative tumor characterized by high anabolic requirements. Short BL doubling time promoted overexpression of cMYC, which controls genes involved in cell cycle progression and cellular metabolism, including glycolysis. Glycolytic intermediates cancer can be diverted to other metabolic pathways, such as serine biosynthesis pathway. Serine supports one carbon network that couples glycolysis folate methionine cycle. Aims: As these circuits are...
Background: SYK kinase is an essential component of integrin b3 signaling, which maintain leukemic stem cell (LSC) transcriptional programs in AML. Genetic or pharmacologic inhibition leads to increased differentiation, reduced proliferation and apoptosis. However, the comprehensive description mediators effectors signaling AML its association with LSC maintenance lacking. Aims: To characterize role identify key downstream responsible for leukemia survival maintenance. Methods: cells (KG1,...
TRAIL (TNF-related apoptosis inducing ligand), member of the tumor necrosis factor superfamily, is known for its strong antitumor activity in many types cancer cells, while exhibiting relatively low cytotoxicity to most normal cells. Therapeutic strategies utilizing or analogs usually exhibit high preclinical vitro and vivo models. In clinical trials, were generally well tolerated, but, surprisingly, exhibited activity. Major limitation TRAIL-based therapies intrinsic secondary resistance...
TRAIL (TNF-related apoptosis inducing ligand), a protein belonging to the tumor necrosis factor family, causes induction through activation of its cognate death receptors (DR4, DR5). Binding leads extrinsic or, in some cell types, intrinsic pathways. Because lower surface expression on non-transformed cells than cancer cells, DR4 and DR5 ligands attract lot attention as potential anti-cancer drugs. Despite exhibiting high activity preclinical vitro vivo models, clinical trials treatment...